Literature DB >> 21752471

PD-L2 is expressed on activated human T cells and regulates their function.

Nassima Messal1, Nacer-Eddine Serriari, Sonia Pastor, Jacques A Nunès, Daniel Olive.   

Abstract

T-cell activation and proliferation are regulated by cosignaling adhesion molecules involved in positive or negative signals. Programmed death (PD)-1 is one of immune inhibitory molecules that is expressed in activated T cells and is a promising target for immunotherapy. Both PD-1 ligands, PD-L1 and PD-L2 are expressed on antigen presenting cells (APCs) involved in the dialogue between a T cell and an APC. Here, we analysed the expression of these ligands, especially for PD-L2, on T cells. PD-L2 appears to be expressed on activated CD4 and CD8T cell subsets. Moreover, as PD-1 molecule, PD-L2 engagement at the surface of T cells is able to down-modulate cytokine production and cell proliferation. These observations indicate that PD-L2 is expressed following activation and is involved in the regulation of T cell function, highlighting the level of complexity in the T cell cosignaling network.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21752471     DOI: 10.1016/j.molimm.2011.06.436

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  45 in total

Review 1.  Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Authors:  David J Byun; Jedd D Wolchok; Lynne M Rosenberg; Monica Girotra
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

Review 2.  Targeting the programmed death-1 pathway in lymphoid neoplasms.

Authors:  Chi Young Ok; Ken H Young
Journal:  Cancer Treat Rev       Date:  2017-02-11       Impact factor: 12.111

3.  Strength of PD-1 signaling differentially affects T-cell effector functions.

Authors:  Fang Wei; Shi Zhong; Zhengyu Ma; Hong Kong; Andrew Medvec; Rafi Ahmed; Gordon J Freeman; Michelle Krogsgaard; James L Riley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

Review 4.  Biomimetic delivery with micro- and nanoparticles.

Authors:  Stephen C Balmert; Steven R Little
Journal:  Adv Mater       Date:  2012-04-23       Impact factor: 30.849

5.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616

Review 6.  Role of the PD-1 pathway in the immune response.

Authors:  L V Riella; A M Paterson; A H Sharpe; A Chandraker
Journal:  Am J Transplant       Date:  2012-08-17       Impact factor: 8.086

7.  B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets.

Authors:  Mikayel Mkrtichyan; Yana G Najjar; Estella C Raulfs; Linda Liu; Solomon Langerman; Geoffrey Guittard; Laurent Ozbun; Samir N Khleif
Journal:  J Immunol       Date:  2012-07-25       Impact factor: 5.422

8.  Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Authors:  Mario Sznol; Lieping Chen
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

9.  Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivity.

Authors:  Jerome Kerzerho; Hadi Maazi; Anneliese O Speak; Natacha Szely; Vincent Lombardi; Bryant Khoo; Stacey Geryak; Jonathan Lam; Pejman Soroosh; Jacques Van Snick; Omid Akbari
Journal:  J Allergy Clin Immunol       Date:  2012-11-20       Impact factor: 10.793

10.  Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients.

Authors:  Miwa Noda; Takaaki Masuda; Shuhei Ito; Taro Tobo; Akihiro Kitagawa; Qingjiang Hu; Dai Shimizu; Hidetoshi Eguchi; Tsuyoshi Etoh; Shinji Ohno; Masafumi Inomata; Koshi Mimori
Journal:  Ann Surg Oncol       Date:  2020-03-21       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.